Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Healthy volunteers will receive a single subcutaneous administration at Dose 1.”In the company’s words, NCT07658482 on ClinicalTrials.gov
- Tested for
- Atopic Dermatitis (AD)
- Main trialPhase 1
- “This is a phase 1, single dose, randomized, open-label, parallel-group study to evaluate the pharmacokinetics (PK), safety, tolerability and immunogenicity of ZL-1503 and to explore its PD biomarkers following a single subcutaneous (SC) or intravenous (IV) administration in healthy volunteers.”In the company’s words, NCT07658482 on ClinicalTrials.gov
Other drugs for Atopic Dermatitis (AD)
Coming up2
- 6 Feb 2027Phase 1 trial completes · ClinicalTrials.gov
- 28 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 6 Feb 2027 | A Phase 1 Study to Evaluate Pharmacokinetics, Safety and Tolerability of ZL-1503 in Healthy Volunteers | |
| Phase 1Recruiting | 28 Dec 2027 | A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026